Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Celanese Eva Performance Polymers LLC shows a distributed prosecution profile with 6 pending office actions. These matters are spread across 5 distinct examiners and 5 distinct art units, all within the Biotechnology & Pharmaceuticals technology area. This distribution indicates that while the technology focus is consistent, the company is interacting with a variety of personnel across multiple specialized units.
The busiest examiner for this portfolio is BARBER, KIMBERLY, who currently handles 2 pending office actions. This represents a higher concentration of work compared to the other distinct examiners who share the remaining workload. The fact that 6 pending office actions are split among 5 distinct art units suggests that the patent applications may cover diverse sub-specialties within the broader biotechnology field.
For patent practitioners, the presence of 5 distinct examiners means that prosecution strategies must be tailored to multiple individual styles and art unit preferences. Although BARBER, KIMBERLY is the busiest examiner with 2 pending office actions, the overall portfolio remains relatively decentralized. Monitoring the outcomes across these 5 distinct art units will be essential for maintaining consistency in the company's intellectual property protections.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (43%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARBER, KIMBERLY | 2 | 73.6% | +18.5% |
| LIPPERT, JOHN WILLIAM | 1 | 58.2% | +40.0% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| PRAGANI, RAJAN | 1 | 53.3% | +70.0% |
| WISTNER, SARAH CLINKSCALES | 1 | 25.0% | +81.0% |
| ZAMORY, JUSTIN L | 1 | 72.9% | +17.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18171406 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | BASQUILL, SEAN M | 17d overdue |
| 17948277 | Refillable Implantable Device for Delivering a Drug Compound | WISTNER, SARAH CLINKSCALES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18157134 | Method for Prohibiting and/or Treating an Eye Condition | BARBER, KIMBERLY | 26d overdue |
| 18171406 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | BASQUILL, SEAN M | 17d overdue |
| 18474292 | Implantable Medical Device for the Delivery of a Nucleic Acid | BARBER, KIMBERLY | — |
| 18332826 | Monolithic Implantable Device for Sustained Release of an Antibody | LIPPERT, JOHN WILLIAM | — |
| 18157123 | Implantable Device for Delivery of a Tyrosine Kinase Inhibitor | PRAGANI, RAJAN | — |
| 17948277 | Refillable Implantable Device for Delivering a Drug Compound | WISTNER, SARAH CLINKSCALES | — |
| 17948271 | Refillable Implantable Device for Delivering a Drug Compound | ZAMORY, JUSTIN L | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1614 | 2 |
| 1637 | 1 |
| 1616 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18474292 | Implantable Medical Device for the Delivery of a Nucleic Acid | BARBER, KIMBERLY | 1637 | §103§112DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18332826 | Monolithic Implantable Device for Sustained Release of an Antibody | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | — | Pending | Jun 12, 2023 |
| 18171406 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | BASQUILL, SEAN M | 1614 | §103§112 | Final Rejection | 17d overdue | Pending | Feb 20, 2023 |
| 18157134 | Method for Prohibiting and/or Treating an Eye Condition | BARBER, KIMBERLY | 1615 | §103 | Final Rejection | 26d overdue | Pending | Jan 20, 2023 |
| 18157123 | Implantable Device for Delivery of a Tyrosine Kinase Inhibitor | PRAGANI, RAJAN | 1614 | §103§112DP | Final Rejection | — | Pending | Jan 20, 2023 |
| 17948277 | Refillable Implantable Device for Delivering a Drug Compound | WISTNER, SARAH CLINKSCALES | 1616 | §103DP | Non-Final OA | — | Pending | Sep 20, 2022 |
| 17948271 | Refillable Implantable Device for Delivering a Drug Compound | ZAMORY, JUSTIN L | 3783 | §103Other | Final Rejection | — | Pending | Sep 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial